Highland Capital Management related stories
All articles and analysis
DFINE Adds $25M in Fresh CapitalDFINE Inc., a maker of minimally invasive radiofrequency targeted therapies for the treatment of vertebral pathologies, closed a $25 million. Investors include OrbiMed Advisors, Prospect Venture Partners, Split Rock Partners, BBT Fund/Apothecary Capital, Highland Capital Management and Vanguard Ventures.
- Highland Capital Says Yoon’s Got Seoul
Highland Capital Management, the Dallas-based investment firm, has added Chris Yoon to its Seoul, South Korea office as director of business development. James Dondero, president and co-founder of Highland, called Korea one of the PE firm’s top regions targeted for investment in Asia.
- Tony Roma's, Known for Its Ribs, Is Up for Sale
Highland Capital Management has put Tony Roma's up for sale, sources say. Five bidders, a mix of strategics and private equity, are vying for the company, one person said. Houlihan Lokey is advising. The auction began one month ago, the source said. One banker said the sale of Tony Roma's is a small deal. The company has less than $20 million EBITDA, the banker said. A strategic is expected to acquire Tony Roma's, the first source said.
- Week in deals, Aug. 30, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- Exit watch, week of Aug. 23, 2010
News briefs about the acquisitions of Conduit Labs, ZyStor and other VC-backed companies in the past week
- Complete Genomics Raises $39 Million
Complete Genomics Inc., a Mountain View, Calif.-based human genome sequencing company, has raised $39 million in Series E funding. Sands Capital led the round, and was joined by return backers Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners. The company previously raised around $90 million, and recently filed for an $86.25 million IPO.
- peHUB Wire: Friday, August 20, 2010
Friday Feedback
- peHUB Wire: Friday, August 20, 2010
Friday Feedback
- US WorldMeds Buys Solstice Neurosciences
US WorldMeds LLC has acquired Solstice Neurosciences Inc., a Malvern, Pa.-based drug company whose first product is a botulinum toxin type B. The deal is valued at $35 million. Solstice Neurosciences had raised around $90 million in VC funding, plus another $35 million in venture debt. Equity backers included Highland Capital Management, Thomas, McNerney & Partners, Investor Growth Capital, Morgan Stanley Venture Partners and Oxford Bioscience Partners.